Andere talen aTyr Pharma, Inc. Deutsche Boerse AG

Aandelen

471A

US0021202025

Beurs gesloten - Deutsche Boerse AG Andere beurzen 15:49:15 10-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,8 ^EUR	+7,78%		+15,38%	+39,53%

05/06	ATyr Pharma, Inc. zal zijn ticker veranderen in ATYR. van LIFE	CI
14/05	ATyr Pharma, Inc. Kondigt Tweede Positieve DSMB Beoordeling aan voor Efzofitimod in Fase 3 EFZO-FIT? studie in longsarcoïdose	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

ATyr Pharma, Inc. will Change its Ticker to ATYR. from LIFE	05/06
ATyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”	03/06
ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	24/05
ATyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference	15/05
ATyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis	14/05
ATyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT? Study in Pulmonary Sarcoidosis	14/05
ATyr Pharma to Present at Upcoming Investor Conferences	06/05
Atyr Pharma: Q1 Earnings Snapshot	02/05
ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000	02/05
ATyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update	02/05
ATyr Pharma to Participate in April Investor Conferences	01/04
ATyr Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Atyr Pharma: Q4 Earnings Snapshot	14/03
ATyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update	14/03
ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03
ATyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results	28/02
ATyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants	21/02
ATyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis	21/02
ATyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity	29/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen aTyr Pharma, Inc. Deutsche Boerse AG

Aandelen

471A

US0021202025

Andere talen

Filters